Value of [18F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy

被引:0
|
作者
Zhang, Yafei [1 ]
Xu, Mimi [1 ]
Wang, Yu [2 ]
Yu, Fang [3 ]
Chen, Xinxin [1 ]
Wang, Guangfa [1 ]
Zhao, Kui [1 ]
Yang, Hong [4 ]
Su, Xinhui [1 ]
机构
[1] Zhejiang Univ, Dept Nucl Med, Affiliated Hosp 1, Sch Med, 79 Qingchun Rd, Hangzhou 310003, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Pharm, Hangzhou 310005, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Hangzhou 310003, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Radiol, 79 Qingchun Rd, Hangzhou 310003, Peoples R China
基金
中国国家自然科学基金;
关键词
F-18]AlF-NOTA-FAPI-04; Pancreatic ductal adenocarcinoma; Pathological response; Neoadjuvant chemotherapy; FDG-PET; F-18-FDG PET/CT; CANCER; CARCINOMA; RESECTION; HEAD;
D O I
10.1007/s00259-025-07084-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives This study aimed to evaluate the predictive value of [F-18]AlF-NOTA-FAPI-04 PET/CT for pathological response to neoadjuvant chemotherapy (NCT) and prognosis in patients with locally advanced pancreatic ductal adenocarcinoma (LAPDAC). Methods This study included 34 patients with histopathologically and radiologically confirmed LAPDAC who received [F-18]AlF-NOTA-FAPI-04 PET/CT scans before NCT. After 4-6 cycles of NCT, these patients underwent radical resection. Pathological response to NCT was assessed by pathological tumor regression grades (TRG) based on the Evans system. PET/CT parameters were evaluated for their association with TRG, recurrence-free survival (RFS) and overall survival (OS) after NCT, including the maximum standardized uptake value (SUVmax), FAPI-avid tumor volume (FTV), total lesion FAP expression (TLF) of primary tumor, total FAPI-avid pancreatic volume (FPV) and total pancreatic FAP expression (TPF) of total pancreas. Results Of 34 patients with LAPDAC, 14 patients had a pathologic good response (PGR, Evans III-IV), and 20 patients had a pathologic poor response (PPR, Evans I-II). Both the primary tumor SUVmax, FTV and TLF, and total pancreas FPV and TPF in the PGR groups were significantly lower than those in the PPR groups. Furthermore, SUVmax and TLF were higher in poorly differentiated LAPDAC than in well-moderately differentiated neoplasms. The FTV, TLF, FPV and TPF were closely associated with RFS and OS. On multivariate analysis, patients with FTV > 54.21 and TLF > 290.21 had a worse RFS and OS, respectively (HR = 3.24, P = 0.014 and HR = 3.35, P = 0.019) and OS (HR = 7.35, P = 0.002 and HR = 7.09, P = 0.004) in LAPDAC after NCT. Conclusions The parameters of [F-18]AlF-NOTA-FAPI-04 PET/CT had the excellent performance for predicting pathologic TRG after NCT in LAPDAC. FTV and TLF were independent postoperative prognostic factors for RFS and OS for LAPDAC.
引用
收藏
页码:2118 / 2131
页数:14
相关论文
共 50 条
  • [1] [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma
    Zhu, Ziyuan
    Cheng, Kai
    Yun, Zhang
    Zhang, Xiang
    Hu, Xiaoyu
    Liu, Jing
    Wang, Fuhao
    Fu, Zheng
    Yue, Jinbo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (11) : 3425 - 3438
  • [2] [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma
    Ziyuan Zhu
    Kai Cheng
    Zhang Yun
    Xiang Zhang
    Xiaoyu Hu
    Jing Liu
    Fuhao Wang
    Zheng Fu
    Jinbo Yue
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 3425 - 3438
  • [3] Value of 18F-FAPI-04 PET-CT for prediction of pathologic response and survival in locally advanced pancreatic ductal adenocarcinoma after neoadjuvant chemotherapy
    Zhang, Y.
    Xu, M.
    Wang, Y.
    Yu, F.
    Chen, X.
    Wang, G.
    Zhao, K.
    Su, X.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S239 - S240
  • [4] [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial
    Dong, Yinjun
    Wang, Zhendan
    Hu, Xinying
    Sun, Yuhong
    Qin, Jingjie
    Qin, Qiming
    Liu, Shuguang
    Yuan, Shuanghu
    Yu, Jinming
    Wei, Yuchun
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (11) : 1702 - 1709
  • [5] Clinical significance of diffuse [18F] AlF-NOTA-FAPI-04 uptake in the thyroid on PET/CT imaging
    Ying Kou
    Wei Diao
    Zhuzhong Cheng
    Yutang Yao
    EJNMMI Research, 15 (1)
  • [6] Value of [18F]AlF-NOTA-FAPI-04 PET/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [18F]FDG PET/CT
    Kailin Qiao
    Xueting Qin
    Shuai Fu
    Jiazhong Ren
    Jing Jia
    Xinying Hu
    Yuanyuan Tao
    Shuanghu Yuan
    Yuchun Wei
    European Radiology, 2024, 34 : 1948 - 1959
  • [7] Value of [18F]AlF-NOTA-FAPI-04 PET/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [18F]FDG PET/CT
    Qiao, Kailin
    Qin, Xueting
    Fu, Shuai
    Ren, Jiazhong
    Jia, Jing
    Hu, Xinying
    Tao, Yuanyuan
    Yuan, Shuanghu
    Wei, Yuchun
    EUROPEAN RADIOLOGY, 2024, 34 (03) : 1948 - 1959
  • [8] Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT
    Lv, Jinghui
    Zheng, Kai
    Jiang, Chengzhi
    Yang, Jian
    Peng, Xiang
    Ye, Hui
    Zhang, Yanyin
    EUROPEAN RADIOLOGY, 2024,
  • [9] [18F]AlF-NOTA-FAPI-04 PET/CT: A Promising Tool for Discriminating Benign and Malignant Breast Lesions
    Liu, Tianxin
    Liu, Jingru
    Zhao, Kunlong
    Yu, Jinming
    Liu, Jie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [10] [18F]AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
    Hu, X.
    Yu, J.
    Wei, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S225 - S225